Growth response of colon cancer cell lines to selective estrogen receptor modulators

Anticancer Research

Volumn 23, Issue 3 B, 2003, Pages 2419-2424

  Picariello, Lucia ^a   Fiorelli, Gianna ^a   Martineti, Valentina ^a   Tognarini, Isabella ^b   Pampaloni, Barbara ^b   Tonelli, Francesco ^a   Brandi, Maria Luisa ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Department of Internal Medicine ^*  (Italy)

Author keywords

Cell growth; Colon cancer; SERMs

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CELL VIABILITY; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

APOPTOSIS; CELL DIVISION; CELL SURVIVAL; COLORECTAL NEOPLASMS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HUMANS; MALE; RALOXIFENE; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0041805660     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Singh S and Langman MJS: Oestrogen and colonic epithelial cell growth. Gut 37: 737-739, 1995.
2. Janne PA and Mayer RJ: Chemoprevention of colorectal cancer. N Engl J Med 342: 1960-1968, 2000.
3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Hutchinson F, Stefanick ML, Jackson R, Beresford SAA, Howard BV, Johnson KC, Kotchen JM and Ockene J: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288: 321-333, 2002.
4. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L and Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90: 1371-1388, 1998.
5. Newcomb PA, Solomon C and White E: Tamoxifen and risk of large bowel cancer in women with breast cancer. Breast Cancer Res Treat 53: 271-277, 1999.
6. Ziv Y, Gupta MK, Milsom JW, Vladisavljevic A, Kitago K and Fazio VW: The effect of tamoxifen on established human colorectal cancer cell lines in vitro. Anticancer Res 16: 3767-3772, 1996.
7. Nakayama Y, Sakamoto H, Satoh K and Yamamoto T: Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor beta mediated system. Cancer Lett 161: 63-71, 2000.
8. Lointier P, Wildrick DM and Boman BM: Growth effects of tamoxifen on LoVo colon carcinoma cells and cultured cells from normal colonic mucosa. Anticancer Res 12(5): 1523-1525, 1992.
9. Di Domenico M, Castoria G, Bilancio A, Migliaccio A and Auricchio F: Estradiol activation of human colon carcinoma-derived Caco-2 cell growth. Cancer Res 56: 4516-4521, 1996.
10. Picariello L, Fiorelli G, Benvenuti S, Brandi ML, Galli G, Malentacchi C, Montali E, Bigozzi U, Ficari F and Tonelli F: In vitro bioeffects of the antiestrogen LY11 7018 on desmoid tumor and colon cancer cells. Anticancer Res 17: 2099-2104, 1997.
11. Fiorelli G, Picariello L, Martineti V, Tonelli F and Brandi ML: Functional estrogen receptor β in colon cancer cells. Biochem Biophys Res Comm 267: 521-527, 1999.
12. Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O and Rice LW: Selective loss of estrogen receptor b in malignant human colon. Cancer Res 60: 245-248, 2000.
13. Barkhem T, Carlsson B, Nilsson Y, Enmmark E, Gustafsson J and Nilsson S: Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists. Mol Pharmacol 54: 105-112, 1998.
14. Paech K, Webb P, Kuiper GJM, Nilsson S, Gustafsson J, Kushner PJ and Scanlan TS: Differential ligand activation of estrogen receptors ERα and ERβ at API sites. Science 277: 1508-1511, 1997.
15. Umar A, Boyer JC, Thomas DC, Nguyen DC, Risinger JI, Boyd J, Ionov Y, Perucho M and Kunkel TA: Defective mismatch repair in extracts of colorectal and endometrial cancer cells lines exhibiting microsatellite instability. J Biol Chem 269: 14367-14370, 1994.
16. Fishel R and Kolodner RD: Identification of mismatch repair genes and their role in the development of cancer. Curr Opin Genet Dev 5: 382-395, 1995.
17. Bhattacharya G and Boman BM: Phosphorylation of the adenomatous polyposis coli protein and its possible regulatory effects in cells. Biochem Biophys Research Commun 208: 103-110, 1995.
18. Fiorelli G, Martineti V, Gori F, Benvenuti S, Frediani U, Formigli, Zecchi S and Brandi ML: Heterogeneity of binding sites and bioeffects of raloxifene on the human leukemic cell line FLG 29.1. Biochem Biophys Res Comm 240: 573-579, 1997.
19. Picariello L, Brandi ML, Formigli L, Zecchi Orlandini S, Dolara P, Caderni G, Raimondi L and Tonelli F: Apoptosis induced by sulindac sulfide in epithelial and mesenchymal cells from human abdominal neoplasms. Eur J Pharm 360: 105-112, 1998.
20. Jordan VC: The development of tamoxifen for breast cancer therapy. In: Long-term Tamoxifen Treatment for Breast Cancer (Jordan VC, eds). Madison, WI, University of Wisconsin Press. 1994, pp 3-26.
21. Osborne CK, Zhao HH and Fuqua SAW: Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 18: 3172-3186, 2000.
22. Avioli LV: SERM drugs for the prevention of osteoporosis. TEM 10: 317-319, 1999.
23. De las Alas MM, Aebi S, Fink D, Howell SB and Los G: Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. J Natl Cancer Inst 89(20): 1537-1541, 1997.
24. Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S and Gustafsson JA: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138: 863-870, 1997.
25. Sutherland RL, Taylor IW, Reddel RR and Hall R: Effects of tamoxifen on the cell cycle kinetics of human mammary carcinoma cells in culture. J Cell Biochem Suppl 6: p. 1034A, 1982.
26. Mandlekar S and Kong AN: Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6: 469-467, 2001.
27. Shang Y and Brown M: Molecular determinants for the tissue specificity of SERMs. Science 295: 2465-2468, 2002.